WuXi AppTec Plans to Build a New Site in Singapore, Better Serve Global Partners and Advance Healthcare Innovation

0

SINGAPORE, July 19, 2022 /PRNewswire/ — WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing at Singapore. The company intends to invest up to 2 billion Singapore dollars (approximately US$1.43 billion) to build and operationalize the site, which aims to enable global partners to advance healthcare innovations. The investment is expected to be made in stages over the next 10 years, depending on the business needs of the company.

The new site will further expand the capacity and enhance the capabilities of WuXi AppTec’s integrated enabling platform and provide state-of-the-art laboratories and facilities that will provide a broad portfolio of R&D and manufacturing services to customers worldwide.

Once finished, the Singapore will play a vital role in WuXi AppTec’s global network through Asia, Europeand North America, meeting growing demand from multinational customers and strengthening collaborations with a wide range of partners. Together, and through their unique CRDMO (Contract Research, Development and Manufacturing Organization) and CTDMO (Contract Testing, Development and Manufacturing Organization) business models, these facilities will provide a range of high quality services with greater flexibility, allowing the to better help partners around the world advance drug discovery and development and deliver breakthrough treatments to patients in need.

“We warmly welcome WuXi AppTec’s plan,” said Dr. Beh Swan Gin, Chairman of the Singapore Economic Development Board (EDB). “The investment will establish Singapore as an important node in the company’s global research, development and manufacturing network. It is a testimony of that of Singapore position as a global biopharmaceutical hub, and will strengthen our attractiveness to biotech innovators and start-ups. »

“We are thrilled to establish this important presence for WuXi AppTec in Singapore and continue to contribute to the vibrant life science ecosystem of the region,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “This investment will further strengthen our capacity and capabilities so that we can better support our collaborative partners globally and realize our shared vision that every medicine can be made and every disease can be treated. »

About WuXi AppTec

As a global company with operations across Asia, Europeand North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discovery and deliver breakthrough treatments to patients. With its unique business models, WuXi AppTec’s end-to-end integrated services include CRDMO (Contract Research, Development and Manufacturing Organization) drug chemistry, biology discovery, preclinical testing and clinical research services, therapeutics cell and gene CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advanced healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2021 and its self-service platform empowers more than 5,800 employees in more than 30 countries to improve the health of those in need – and realize the vision that ” every medicine can be made and every disease can be treated.” Please visit: http://www.wuxiapptec.com

SOURCE WuXi AppTec

Share.

Comments are closed.